Welcome to the Psychiatry Consortium
Accelerating innovative drug discovery
The Psychiatry Consortium is a strategic collaboration of leading medical research charities and pharmaceutical companies focusing on the challenge of identifying and validating novel drug targets to address the unmet therapeutic needs of the people living with mental health conditions.
The scale and impact of mental illness across society is huge. One in ten children, and one in four adults (approx. 15 million people) experience mental illness each year, affecting their wellbeing, relationships, and potential ability to work.
We bring together key Research and Development players in a focussed effort to identify and validate novel drug targets to address the unmet therapeutic needs of those living with mental illness, including psychiatric symptoms associated with dementia.
Delivering the next generation drug discovery pipeline; New approaches to target identification and target validation
A workshop co-hosted by the Psychiatry Consortium and the Psychiatric Genomics Consortium.Psychiatric drug discovery has the potential to be re-invigorated by recent advances in genomics. Increases in whole genome sequencing and larger genome-wide association studies (GWAS) have yielded an unprecedented trove of new knowledge about the genetic underpinnings of psychiatric diseases and, with it, a […]Read more
Innovative drug discovery consortium to address unmet therapeutic needs of people living with mental health conditions
In June 2019, Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK formed an innovative drug discovery consortium with industry, supported by Wellcome.The Psychiatry Consortium aims to identify and validate novel drug targets to address unmet therapeutic needs and psychiatric symptoms affecting people with mental health conditions and dementia.The Psychiatry Consortium is part of MDC’s […]Read more